---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-022648"
form_type: "8-K"
ticker: "NRXP"
cik: "0001719406"
company_name: "NRX Pharmaceuticals, Inc."
filed_at: "2024-02-14T23:59:59+00:00"
generated_at: "2026-06-06T02:28:31.430135+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# NRx receives $5M advance milestone from Alvogen/Lotus, issues 4.2M warrants at $0.40

## Summary
- $5M received immediately; funds NRX-101 development through Phase 2 FDA meeting.
- Alvogen receives 4,195,978 warrants at $0.40 strike, 3-year term.
- Second $4M milestone due within 60 days of positive end-of-Phase 2 FDA meeting.
- NRx eligible for up to $320M in future milestones and tiered double-digit royalties.
- Alvogen/Lotus to cover future NRX-101 development and commercialization costs.

## SEC filing metadata
- accession: 0001104659-24-022648
- form_type: 8-K
- ticker: NRXP
- cik: 0001719406
- company_name: NRX Pharmaceuticals, Inc.
- filed_at: 2024-02-14T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1719406/000110465924022648/0001104659-24-022648-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1719406/000110465924022648/tm246184d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-022648
- JSON: https://secwatch.observer/filing/0001104659-24-022648.json
- Plain text: https://secwatch.observer/filing/0001104659-24-022648.txt

## Key facts
- Material Agreements
  NRX Pharmaceuticals, Inc. amended First Amendment with Alvogen Pharma US, Inc., Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd. valued at $5 million (effective 2024-02-07).
  - Action: amendment
  - Agreement: license
  - Counterparty: Alvogen Pharma US, Inc., Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd.
  - Value: $5 million
  - Effective: 2024-02-07
  source text: On February 7, 2024, NeuroRx, Inc., a wholly-owned subsidiary of NRx Pharmaceuticals, Inc. (together, the “ Company ”), entered into the First Amendment (the “ Amendment ”) to the Exclusive, Global Development, Supply, Marketing & License Agreement, dated as of June 2, 2023 (the “ License Agreement ”), with Alvogen Pharma US, Inc., Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd. (collectively, “ Alvogen ”), effective as of the same date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1719406/000110465924022648/0001104659-24-022648-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.